via Wall Street Journal
Robin Miller, a 62-year-old oncologist in Atlanta with bladder cancer, was scheduled to receive a potentially lifesaving drug in December. But her doctor’s office called shortly before the appointment to say: “Sorry, we don’t have any. We can’t give it to you,” according to Dr. Miller.
The disruption was due to a global shortage of the drug, BCG, which arose after manufacturing problems at two of the few global suppliers. Without the drug, Dr. Miller feared her cancer would come back and she would have to have her bladder removed, a step she called “barbaric.”
The BCG shortage followed a 2012 mold infestation that halted production for more than two years at an aging factory in Toronto owned by France’s Sanofi SA. The drug’s only other manufacturer for the U.S., Merck & Co., has recently suffered production delays of its own.
Some of the thousands of patients who depend on BCG have resorted to tracking online message boards, calling hospitals and traveling hundreds of miles to find supplies..
To read the full article CLICK HERE